<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Ebola Virus Disease (EVD) - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    

    
    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Ebola Virus Disease (EVD)</span>
        </nav>

        <header class="page-header">
            <h1>Ebola Virus Disease (EVD)</h1>
            <div class="header-meta">
                
                
                <span class="badge badge-mondo">
                    <a href="https://monarchinitiative.org/disease/MONDO:0005737" target="_blank">
                        MONDO:0005737
                    </a>
                </span>
                
                
            </div>
        </header>

        <!-- Stats bar -->
        <div class="stats-bar">
            <div class="stat-item">
                <div class="stat-value">5</div>
                <div class="stat-label">Mechanisms</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">18</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">6</div>
                <div class="stat-label">Genes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">3</div>
                <div class="stat-label">Treatments</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">5</div>
                <div class="stat-label">Subtypes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
        </div>

        <!-- Subtypes -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #eef2ff; color: #4f46e5;">◆</div>
                <h2 class="card-title">Subtypes</h2>
                <span class="card-count">5</span>
            </div>
            
            <div class="item-box subtype-box">
                <div class="item-name">Zaire Ebolavirus</div>
                
                <div class="item-desc">The most common and deadliest strain, responsible for the majority of Ebola outbreaks.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/8800808" target="_blank">PMID:8800808</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The reemergence of Ebola, subtype Zaire, in Kikwit 1995 caused a worldwide sensation, since it struck after a sensibilization on the danger of Ebola virus disease."</div>
                
                
                <div class="evidence-explanation">The Zaire ebolavirus is indeed one of the subtypes of Ebola virus. It is highlighted as a significant strain causing major concern during outbreaks.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/23327370" target="_blank">PMID:23327370</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The re-emergence of EHF outbreaks in Gabon and Republic of the Congo were concomitant with an increase in mortality amongst gorillas and chimpanzees infected with ZEBOV."</div>
                
                
                <div class="evidence-explanation">This reference highlights the re-emergence of outbreaks in the specified locations and underscores the high mortality rates associated with the Zaire strain of the Ebola virus.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/24795448" target="_blank">PMID:24795448</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The causative agent has now been identified as an outlier strain of Zaire Ebola virus."</div>
                
                
                <div class="evidence-explanation">This reference confirms that the virus responsible for the outbreak is a strain of Zaire Ebola virus, supporting the statement&#39;s claim about the locations and the strain.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box subtype-box">
                <div class="item-name">Sudan Ebolavirus</div>
                
                <div class="item-desc">Second most prevalent strain, associated with large outbreaks in Africa.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/37750724" target="_blank">PMID:37750724</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Here, the 2022 Sudan virus disease (SVD) outbreak in Mubende District, Uganda, is summarized."</div>
                
                
                <div class="evidence-explanation">This reference indicates that Sudan virus disease (SVD), one of the strains of Ebola Virus Disease (EVD), is associated with outbreaks in Uganda.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/28643203" target="_blank">PMID:28643203</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Ebola virus disease (EVD) in humans is associated with four ebolaviruses: Ebola virus (EBOV), Sudan virus (SUDV), Bundibugyo virus (BDBV), and Taï Forest virus"</div>
                
                
                <div class="evidence-explanation">This reference confirms that the Sudan virus (SUDV) is a known subtype of Ebola virus disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/31806422" target="_blank">PMID:31806422</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The genus Ebolavirus from the family Filoviridae is composed of five species including Sudan ebolavirus."</div>
                
                
                <div class="evidence-explanation">This reference lists Sudan ebolavirus as one of the species in the genus Ebolavirus, supporting the statement that it is a subtype.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box subtype-box">
                <div class="item-name">Bundibugyo Ebolavirus</div>
                
                <div class="item-desc">Identified in Uganda, this strain has caused smaller outbreaks.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/21122234" target="_blank">PMID:21122234</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The first known Ebola hemorrhagic fever (EHF) outbreak caused by Bundibugyo Ebola virus occurred in Bundibugyo District, Uganda, in 2007. Fifty-six cases of EHF were laboratory confirmed."</div>
                
                
                <div class="evidence-explanation">This reference supports the statement by confirming the occurrence of a Bundibugyo Ebola virus outbreak in Uganda.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/34467242" target="_blank">PMID:34467242</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Bundibugyo virus (BDBV) is one of four ebolaviruses known to cause disease in humans. Bundibugyo virus disease (BVD) outbreaks occurred in 2007-2008 in Bundibugyo District, Uganda, and in 2012 in Isiro, Province Orientale, Democratic Republic of the Congo."</div>
                
                
                <div class="evidence-explanation">This reference also supports the statement by citing outbreaks of Bundibugyo Ebola virus in Uganda.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box subtype-box">
                <div class="item-name">Taï Forest Ebolavirus</div>
                
                <div class="item-desc">Known for a single outbreak in the Ivory Coast.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/28643203" target="_blank">PMID:28643203</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Ebola virus disease (EVD) in humans is associated with four ebolaviruses: Ebola virus (EBOV), Sudan virus (SUDV), Bundibugyo virus (BDBV), and Taï Forest virus"</div>
                
                
                <div class="evidence-explanation">The literature states that Tai Forest virus is indeed one of the ebolaviruses and mentions its association with human Ebola virus disease (EVD), supporting the claim of a known outbreak in Ivory Coast.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/31806422" target="_blank">PMID:31806422</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The genus Ebolavirus from the family Filoviridae is composed of five species including Sudan ebolavirus, Reston ebolavirus, Bundibugyo ebolavirus, Taï Forest ebolavirus, and Ebola virus (previously known as Zaire ebolavirus)"</div>
                
                
                <div class="evidence-explanation">The reference lists Tai Forest ebolavirus as one of the species within the genus Ebolavirus, supporting the claim that it is a subtype of Ebola virus disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/37750724" target="_blank">PMID:37750724</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                </div>
                
                <div class="evidence-snippet">"Here, the 2022 Sudan virus disease (SVD) outbreak in Mubende District, Uganda, is summarized, and the genetic relatedness of the new variant is evaluated."</div>
                
                
                <div class="evidence-explanation">This reference discusses the Sudan virus disease outbreak in Uganda in 2022 and does not mention the Tai Forest ebolavirus or outbreaks in Ivory Coast.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box subtype-box">
                <div class="item-name">Reston Ebolavirus</div>
                
                <div class="item-desc">Only strain identified outside Africa; found in the Philippines and has not caused disease in humans.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/21987747" target="_blank">PMID:21987747</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"Reston ebolavirus infection event in domestic pigs has triggered continuing epidemiologic investigations among Philippine health and veterinary agencies... The first one in 1989 was the first-ever Ebola virus that emerged outside of Africa and was also the first known natural infection of Ebola..."</div>
                
                
                <div class="evidence-explanation">The reference supports that Reston ebolavirus was identified outside of Africa in the Philippines and that it had not caused disease in humans, but it does not affirmatively state that it is the only strain identified outside of Africa.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/28643203" target="_blank">PMID:28643203</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"To date, no documented cases of human disease have been associated with Reston virus."</div>
                
                
                <div class="evidence-explanation">This reference supports the claim that Reston ebolavirus has not caused disease in humans.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Pathophysiology -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">⚙</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">5</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Viral Entry via Endocytosis</div>
                
                <div class="item-desc">Ebola virus enters host cells through receptor-mediated macropinocytosis. The virus attaches to phosphatidylserine receptors like TIM-1 (HAVCR1) and is internalized into endosomes. Cathepsins B and L cleave the viral glycoprotein (GP), followed by binding to the essential receptor NPC1 in late endosomes/lysosomes, triggering membrane fusion and release of viral genome into the cytoplasm.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        monocyte
                        
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000576" target="_blank" style="color: inherit; margin-left: 4px;">↗</a>
                        
                    </span>
                    
                    <span class="tag tag-cell">
                        macrophage
                        
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000235" target="_blank" style="color: inherit; margin-left: 4px;">↗</a>
                        
                    </span>
                    
                    <span class="tag tag-cell">
                        dendritic cell
                        
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000451" target="_blank" style="color: inherit; margin-left: 4px;">↗</a>
                        
                    </span>
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">symbiont entry into host cell</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Immune Evasion and Viral Replication</div>
                
                <div class="item-desc">Ebola viral proteins VP35 and VP24 antagonize the host interferon response. VP35 binds dsRNA and blocks RIG-I signaling, while VP24 prevents STAT1 nuclear import, thereby suppressing type I interferon signaling. This allows rapid viral replication and high viremia in infected monocytes, macrophages, and dendritic cells.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        monocyte
                        
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000576" target="_blank" style="color: inherit; margin-left: 4px;">↗</a>
                        
                    </span>
                    
                    <span class="tag tag-cell">
                        macrophage
                        
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000235" target="_blank" style="color: inherit; margin-left: 4px;">↗</a>
                        
                    </span>
                    
                    <span class="tag tag-cell">
                        dendritic cell
                        
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000451" target="_blank" style="color: inherit; margin-left: 4px;">↗</a>
                        
                    </span>
                    
                </div>
                
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Endothelial Dysfunction and Vascular Leak</div>
                
                <div class="item-desc">Ebola virus glycoprotein (GP) and secreted GP (sGP) contribute to endothelial cell activation and barrier disruption. This leads to increased vascular permeability, fluid extravasation, and hypovolemic shock. Endothelial dysfunction is a central feature of Ebola hemorrhagic fever.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        endothelial cell
                        
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000115" target="_blank" style="color: inherit; margin-left: 4px;">↗</a>
                        
                    </span>
                    
                </div>
                
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Coagulopathy and Disseminated Intravascular Coagulation</div>
                
                <div class="item-desc">Ebola infection triggers systemic inflammatory response with cytokine release, endothelial activation, and tissue factor pathway activation. This leads to thromboinflammation, platelet activation, consumptive coagulopathy, and disseminated intravascular coagulation (DIC), resulting in hemorrhagic manifestations.</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">blood coagulation</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Multiorgan Involvement</div>
                
                <div class="item-desc">Ebola virus infects multiple organs including liver, spleen, lymph nodes, and kidneys. Hepatic dysfunction with elevated liver enzymes (AST &gt; ALT pattern) and splenic involvement contribute to multiorgan failure in severe cases.</div>
                
                
                
                
    
    
            </div>
            
        </div>
        

        <!-- Causal Graph -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #e0e7ff; color: #4f46e5;">⬡</div>
                <h2 class="card-title">Causal Graph</h2>
            </div>
            
            <div class="graph-warning">
                <strong>Referential integrity issues (1):</strong>
                <ul>
                    
                    <li>Target &#39;Vascular Dysfunction and Death&#39; (from &#39;Hemorrhage&#39;) not found in named elements</li>
                    
                    
                </ul>
            </div>
            
            <div class="mermaid-container">
                <pre class="mermaid">graph TD
    Elevated_Liver_Enzymes[&#34;Elevated Liver Enzymes&#34;]
    Diarrhea[&#34;Diarrhea&#34;]
    Electrolyte_Imbalances[&#34;Electrolyte Imbalances&#34;]
    Thrombocytopenia[&#34;Thrombocytopenia&#34;]
    Dehydration[&#34;Dehydration&#34;]
    Vascular_Dysfunction_and_Death[&#34;Vascular Dysfunction and Death&#34;]
    Impaired_Liver_Function[&#34;Impaired Liver Function&#34;]
    Hypovolemic_Shock[&#34;Hypovolemic Shock&#34;]
    Hepatitis[&#34;Hepatitis&#34;]
    Hemorrhage[&#34;Hemorrhage&#34;]
    Increased_Risk_of_Bleeding[&#34;Increased Risk of Bleeding&#34;]
    Multiorgan_Failure[&#34;Multiorgan Failure&#34;]

    Hemorrhage --&gt; Hypovolemic_Shock
    Hemorrhage --&gt; Multiorgan_Failure
    Hemorrhage -.-&gt; Vascular_Dysfunction_and_Death
    Diarrhea --&gt; Dehydration
    Diarrhea --&gt; Electrolyte_Imbalances
    Thrombocytopenia --&gt; Increased_Risk_of_Bleeding
    Hepatitis --&gt; Elevated_Liver_Enzymes
    Hepatitis --&gt; Impaired_Liver_Function

    style Elevated_Liver_Enzymes fill:#fef3c7
    style Diarrhea fill:#fef3c7
    style Electrolyte_Imbalances fill:#fef3c7
    style Thrombocytopenia fill:#fef3c7
    style Dehydration fill:#fef3c7
    style Vascular_Dysfunction_and_Death fill:#fee2e2,stroke:#dc2626,stroke-dasharray: 5 5
    style Impaired_Liver_Function fill:#fef3c7
    style Hypovolemic_Shock fill:#fef3c7
    style Hepatitis fill:#fef3c7
    style Hemorrhage fill:#fef3c7
    style Increased_Risk_of_Bleeding fill:#fef3c7
    style Multiorgan_Failure fill:#fef3c7</pre>
            </div>
        </div>
        

        <!-- Phenotypes -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">●</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">18</span>
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Fever
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Systemic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0001945" target="_blank">
                            HP:0001945
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/32080199" target="_blank">PMID:32080199</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"EVD has a high case-fatality rate; it is characterized by fever, gastrointestinal signs and multiple organ dysfunction syndrome."</div>
                
                
                <div class="evidence-explanation">The literature indicates that fever is a very frequent symptom of Ebola Virus Disease (EVD).</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/28457350" target="_blank">PMID:28457350</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"This review highlights the range of aspects of EVD that the authors find are relevant to laboratory medicine, including the need for robust prediagnostic and laboratory processing algorithms to inform sampling of suspect patients, the vast majority of whom, in resource-rich settings, will have..."</div>
                
                
                <div class="evidence-explanation">The background is specific to diagnostic issues for laboratory professionals, indicating the relevance of fever as a primary symptom for suspect cases during prediagnostic processes.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Hemorrhage
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Systemic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0001892" target="_blank">
                            HP:0001892
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-meta">
                    <strong style="font-size: 0.8rem; color: #166534;">Sequelae:</strong>
                    
                    <span class="tag" style="background: #bbf7d0; color: #166534;">Hypovolemic Shock</span>
                    
                    <span class="tag" style="background: #bbf7d0; color: #166534;">Multiorgan Failure</span>
                    
                    <span class="tag" style="background: #bbf7d0; color: #166534;">Vascular Dysfunction and Death</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/32487785" target="_blank">PMID:32487785</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"It is usually diagnosed based on several clinical symptoms such as the sudden onset of illness, high fevers for less than three weeks, and at least two hemorrhagic symptoms despite no predisposing factors."</div>
                
                
                <div class="evidence-explanation">The literature confirms that hemorrhagic symptoms are a key diagnostic feature of EVD.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/28484180" target="_blank">PMID:28484180</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Ebolaviruses, members of the family Filoviridae, cause severe hemorrhagic fever in humans and nonhuman primates, with human case fatality rates of up to 90%."</div>
                
                
                <div class="evidence-explanation">The literature confirms severe hemorrhagic fever as a phenotype of EVD.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/30893774" target="_blank">PMID:30893774</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Ebola Virus Disease (EVD) is one of the most lethal transmissible infections, characterized by a high fatality rate, and caused by a member of the Filoviridae family."</div>
                
                
                <div class="evidence-explanation">The literature supports that EVD is a severe systemic disease with high fatality, implying high frequency and severity of symptoms like hemorrhage.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Vomiting
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Gastrointestinal</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0002013" target="_blank">
                            HP:0002013
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/25972150" target="_blank">PMID:25972150</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"Common gastrointestinal manifestations include...nausea and vomiting-60%...The diarrhea and nausea and vomiting frequently produce profound, life-threatening hypovolemia."</div>
                
                
                <div class="evidence-explanation">While vomiting is a common manifestation and can lead to severe consequences like life-threatening hypovolemia, the literature does not specifically categorize vomiting itself as &#34;severe.&#34; The severity is associated with the complications resulting from vomiting and other symptoms.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/32080199" target="_blank">PMID:32080199</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"EVD outbreaks typically start from a single case of probable zoonotic transmission, followed by human-to-human transmission via direct contact or contact with infected bodily fluids or contaminated fomites. EVD has a high case-fatality rate; it is characterized by fever, gastrointestinal signs..."</div>
                
                
                <div class="evidence-explanation">This reference indicates the inclusion of gastrointestinal signs in EVD, which can imply vomiting, but does not specifically mention the frequency or severity of vomiting.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/27717513" target="_blank">PMID:27717513</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"The clinical spectrum of Ebola virus disease (EVD) ranges from very serious forms with organ failure and death within days to paucisymptomatic forms and perhaps even asymptomatic."</div>
                
                
                <div class="evidence-explanation">This suggests variability in EVD presentation, acknowledging severe forms, but it does not specify the severity or frequency of vomiting in particular.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Diarrhea
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Gastrointestinal</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0002014" target="_blank">
                            HP:0002014
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-meta">
                    <strong style="font-size: 0.8rem; color: #166534;">Sequelae:</strong>
                    
                    <span class="tag" style="background: #bbf7d0; color: #166534;">Dehydration</span>
                    
                    <span class="tag" style="background: #bbf7d0; color: #166534;">Electrolyte Imbalances</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/32080199" target="_blank">PMID:32080199</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"EVD has a high case-fatality rate; it is characterized by fever, gastrointestinal signs and multiple organ dysfunction syndrome."</div>
                
                
                <div class="evidence-explanation">The reference mentions that EVD is characterized by gastrointestinal signs, indicating the relevance of diarrhea as a symptom.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/25972150" target="_blank">PMID:25972150</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Common gastrointestinal manifestations include diarrhea-70 %."</div>
                
                
                <div class="evidence-explanation">This directly supports the statement by noting that diarrhea is a common (70% frequency) gastrointestinal manifestation.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/34986351" target="_blank">PMID:34986351</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"During the 2013-2016 West African (WA) Ebola virus (EBOV) outbreak, severe gastrointestinal symptoms were common in patients and associated with poor outcome."</div>
                
                
                <div class="evidence-explanation">The reference highlights that severe gastrointestinal symptoms, including diarrhea, were common and associated with poor outcomes.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Maculopapular Rash
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Dermatologic</span>
                    
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/25780982" target="_blank">PMID:25780982</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The main cutaneous finding of Ebola is a nonspecific maculopapular rash that appears between day four and six of disease."</div>
                
                
                <div class="evidence-explanation">The statement is supported as the primary dermatologic phenotype associated with Ebola Virus Disease (EVD) is a nonspecific maculopapular rash, and it is noted as a main cutaneous finding.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Fatigue
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Systemic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0012378" target="_blank">
                            HP:0012378
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/38840082" target="_blank">PMID:38840082</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"The pooled prevalence was... fatigue 25% (95% CI: 19%-31%)"</div>
                
                
                <div class="evidence-explanation">Fatigue is reported as a symptom in 25% of EVD survivors, which indicates it is relatively common but not &#39;very frequent&#39; as the statement suggests.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Myalgia
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Musculoskeletal</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0003326" target="_blank">
                            HP:0003326
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/38840082" target="_blank">PMID:38840082</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The pooled prevalence was: arthralgia 50% (95% CI: 41%-59%); headache 44% (95% CI: 36%-52%); myalgia 32% (95% CI: 26%-38%)"</div>
                
                
                <div class="evidence-explanation">The meta-analysis shows that myalgia has a pooled prevalence of 32% among Ebola Virus Disease (EVD) survivors, indicating it is a frequent musculoskeletal symptom.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Headache
                    
                    <span class="phenotype-freq">OCCASIONAL</span>
                    
                    
                    <span class="phenotype-category">Neurologic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0002315" target="_blank">
                            HP:0002315
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/31874716" target="_blank">PMID:31874716</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The main clinical signs were asthenia (78.8%), fever (75.3%), anorexia (53.4%), headache (45.9%)..."</div>
                
                
                <div class="evidence-explanation">This study lists headache as one of the main clinical signs in children with EVD, supporting the statement that headache is an occasional neurologic symptom of EVD.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/33493959" target="_blank">PMID:33493959</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"In patients with EVD, neurologic manifestations range from mild symptoms such as confusion to severe neurologic diseases such as meningitis and encephalitis. Altered mental status, from mild confusion to delirium with hallucinations, may also occur."</div>
                
                
                <div class="evidence-explanation">While this reference does not explicitly mention headache, it discusses a range of neurologic symptoms in EVD patients, suggesting that neurologic symptoms, including headache, can occur occasionally.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/26983037" target="_blank">PMID:26983037</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Survivors reported musculoskeletal pain (70%), headache (48%), and ocular problems (14%)."</div>
                
                
                <div class="evidence-explanation">This study reports that 48% of EVD survivors experienced headaches, supporting the statement that headache is an occasional neurologic symptom of EVD.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Abdominal Pain
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Gastrointestinal</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0002027" target="_blank">
                            HP:0002027
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/25972150" target="_blank">PMID:25972150</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Common gastrointestinal manifestations include diarrhea-70 %, nausea and vomiting-60 %, and abdominal pain-45 %."</div>
                
                
                <div class="evidence-explanation">The literature indicates that abdominal pain occurs in 45% of EVD cases, supporting the claim that it is a frequent gastrointestinal manifestation.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/31874716" target="_blank">PMID:31874716</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The main clinical signs were asthenia (78.8%), fever (75.3%), anorexia (53.4%), headache (45.9%), vomiting (41.8%), abdominal pain (29.5%), and diarrhea (28.8%)."</div>
                
                
                <div class="evidence-explanation">The study shows that abdominal pain was observed in 29.5% of children with EVD, supporting the statement that it is a frequent gastrointestinal symptom.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Thrombocytopenia
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Hematologic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0001873" target="_blank">
                            HP:0001873
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-meta">
                    <strong style="font-size: 0.8rem; color: #166534;">Sequelae:</strong>
                    
                    <span class="tag" style="background: #bbf7d0; color: #166534;">Increased Risk of Bleeding</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/32487785" target="_blank">PMID:32487785</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"Transmission of EBoV has been reported in various ways, including human to human transmission through close contact with blood and bodily fluids... It is usually diagnosed based on several clinical symptoms such as the sudden onset of illness, high fevers for less than three weeks, and at least..."</div>
                
                
                <div class="evidence-explanation">The literature mentions hemorrhagic symptoms but does not specifically mention thrombocytopenia or its frequency.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/25679971" target="_blank">PMID:25679971</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"Understanding bleeding in Ebola virus disease."</div>
                
                
                <div class="evidence-explanation">The reference discusses bleeding in Ebola virus disease but does not specifically mention thrombocytopenia or its frequency.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/35446128" target="_blank">PMID:35446128</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"Ebola virus (EBV) disease (EVD) is a highly virulent systemic disease characterized by an aggressive systemic inflammatory response and impaired vascular and coagulation systems, often leading to uncontrolled hemorrhaging and death."</div>
                
                
                <div class="evidence-explanation">The literature discusses impaired vascular and coagulation systems, which can be related to thrombocytopenia, but does not specifically mention its frequency.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Hepatitis
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Hepatic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0012115" target="_blank">
                            HP:0012115
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-meta">
                    <strong style="font-size: 0.8rem; color: #166534;">Sequelae:</strong>
                    
                    <span class="tag" style="background: #bbf7d0; color: #166534;">Elevated Liver Enzymes</span>
                    
                    <span class="tag" style="background: #bbf7d0; color: #166534;">Impaired Liver Function</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/2822180" target="_blank">PMID:2822180</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"Even though HAV, HBV and HNANB viruses are responsible for most of the viral hepatitis cases, many other viruses have been reported to cause hepatic injury. These viruses may involve the liver, either as part of a systemic illness (e.g. EBV, CMV, HSV) or as the primary target organ (e.g. yellow..."</div>
                
                
                <div class="evidence-explanation">The reference indicates that Ebola virus can cause hepatic injury, but clinically overt hepatocellular dysfunction is rare. This partially supports the statement as it acknowledges hepatic involvement but suggests that severe liver dysfunction is not frequent.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/25972150" target="_blank">PMID:25972150</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"The mean serum AST and ALT levels are each about 200/UL, with an unusual pattern for viral hepatitis of AST &gt; ALT."</div>
                
                
                <div class="evidence-explanation">The reference indicates elevated liver enzymes (AST and ALT) in Ebola virus infection, which supports the part of the statement regarding elevated liver enzymes. However, it does not confirm frequent impaired liver function or hepatitis as a common sequela.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/37170900" target="_blank">PMID:37170900</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"Results illustrate that EBOV causes macrophage phenotype alterations as well as neutrophil influx and prominent activation of interferon host responses in the liver."</div>
                
                
                <div class="evidence-explanation">The reference provides evidence of liver involvement and immune response alterations in Ebola virus infection, which can be associated with hepatic dysfunction. However, it does not explicitly state that hepatitis or impaired liver function is frequent.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Hypovolemic Shock
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Systemic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0031273" target="_blank">
                            HP:0031273
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Dehydration
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Systemic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0001944" target="_blank">
                            HP:0001944
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Electrolyte Imbalances
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Metabolic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0003111" target="_blank">
                            HP:0003111
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Multiorgan Failure
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    
                </div>
                
                <div class="item-desc">HPO does not have a specific term for multiple organ dysfunction syndrome</div>
                
                
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Elevated Liver Enzymes
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0002910" target="_blank">
                            HP:0002910
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Impaired Liver Function
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0001410" target="_blank">
                            HP:0001410
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Increased Risk of Bleeding
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0001892" target="_blank">
                            HP:0001892
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    
            </div>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">🧬</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">6</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    NPC1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Host factor)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    HAVCR1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Host factor)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    SLC39A9
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Host factor)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    PIK3C3
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Host factor)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    CTSB
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Host factor)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    CTSL
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Host factor)</span>
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">💊</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">3</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Supportive Care
                    
                    <span class="phenotype-id">
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/maxo/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FMAXO_0000950" target="_blank">
                            MAXO:0000950
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Includes rehydration, symptomatic treatment to manage fever, bleeding, and pain.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/37355146" target="_blank">PMID:37355146</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Early detection and supportive care can enhance the likelihood of survival. This includes intravenous fluids, electrolyte replacement, and treatment of secondary infections."</div>
                
                
                <div class="evidence-explanation">The provided literature supports that supportive care, including rehydration and symptomatic treatment, is a key component in the treatment of Ebola Virus Disease (EVD).</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/28646340" target="_blank">PMID:28646340</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Clinical management of EVD combines supportive and symptomatic care while also addressing the patient&#39;s emotional and mental health needs."</div>
                
                
                <div class="evidence-explanation">This literature indicates the combination of supportive and symptomatic care is part of the clinical management of EVD.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/29054555" target="_blank">PMID:29054555</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Key recommendations include administration of oral and, as necessary, intravenous hydration; systematic monitoring of vital signs and volume status; availability of key biochemical testing; adequate staffing ratios; and availability of analgesics, including opioids, for pain relief."</div>
                
                
                <div class="evidence-explanation">The evidence-based guidelines for supportive care of patients with EVD include recommendations that align with rehydration and symptomatic treatments for managing fever, bleeding, and pain.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Experimental Therapies
                    
                    <span class="phenotype-id">
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/maxo/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FMAXO_0000168" target="_blank">
                            MAXO:0000168
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Includes antiviral drugs, immune therapies, and blood products from survivors containing antibodies.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/27337455" target="_blank">PMID:27337455</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The armamentarium against EVD eventually included biologics such as monoclonal antibodies, convalescent plasma, and vaccines as well as small molecule therapeutics such as small interfering RNAs and nucleoside analogs."</div>
                
                
                <div class="evidence-explanation">The reference mentions the use of various experimental therapies including immune therapies (monoclonal antibodies), blood products (convalescent plasma), and small molecule therapeutics (antiviral drugs).</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/11766882" target="_blank">PMID:11766882</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"This review describes Ebola viruses, with a particular focus on the status of research efforts to develop vaccines and therapeutics and to identify the immune mechanisms of protection."</div>
                
                
                <div class="evidence-explanation">The reference highlights the ongoing research for developing therapeutics, including immune mechanisms for protection, which aligns with the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/25457751" target="_blank">PMID:25457751</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Recently, the use of convalescent blood products was proposed by the WHO as one early option for treating patients with Ebola virus disease."</div>
                
                
                <div class="evidence-explanation">The reference confirms the use of convalescent blood products as a treatment strategy for EVD, supporting the statement.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Vaccination
                    
                    <span class="phenotype-id">
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/maxo/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FMAXO_0001017" target="_blank">
                            MAXO:0001017
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">The rVSV-ZEBOV vaccine has been shown to be effective in preventing Ebola infection.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/28017403" target="_blank">PMID:28017403</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The results add weight to the interim assessment that rVSV-ZEBOV offers substantial protection against Ebola virus disease, with no cases among vaccinated individuals from day 10 after vaccination in both randomised and non-randomised clusters."</div>
                
                
                <div class="evidence-explanation">The study shows that rVSV-ZEBOV vaccine offers substantial protection against Ebola virus disease, supporting the statement that it is effective in preventing Ebola infection.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/32243796" target="_blank">PMID:32243796</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Ervebo is the first licensed vaccine for prevention of Ebola virus disease."</div>
                
                
                <div class="evidence-explanation">The article states that Ervebo (rVSV-ZEBOV) is licensed for the prevention of Ebola virus disease, supporting the statement that the vaccine is effective in preventing Ebola infection.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/33873076" target="_blank">PMID:33873076</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Currently, two vaccines: Ervebo (rVSV-ZEBOV) and a two-dose combination of Zabdeno (Ad26.ZEBOV) and Mvabea (MVA-BN-Filo) have been licensed and in use."</div>
                
                
                <div class="evidence-explanation">The abstract mentions that Ervebo (rVSV-ZEBOV) has been licensed and is being used to prevent Ebola Virus Disease, supporting the statement that it is effective in preventing infection.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ccfbf1; color: #0d9488;">🌍</div>
                <h2 class="card-title">Environmental Factors</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Animal Reservoirs</div>
                
                <div class="item-desc">Fruit bats are considered the natural hosts; transmission also occurs through handling of infected wild animals.</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/17848072" target="_blank">PMID:17848072</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Among the various animals captured and analyzed, three species of fruit bats (suborder Megachiroptera) were found asymptomatically and naturally infected with Ebola virus: Hypsignathus monstrosus (hammer-headed fruit beats), Epomops franqueti (singing fruit bats), and Myonycteris torquata..."</div>
                
                
                <div class="evidence-explanation">This study confirms that certain species of fruit bats serve as Ebola virus reservoirs, supporting the notion that fruit bats are natural hosts of the virus.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/28573636" target="_blank">PMID:28573636</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"Although an ebolavirus natural reservoir has yet to be identified, the majority of disease ecologists believe the reservoir to belong to the order Chiroptera (bats)."</div>
                
                
                <div class="evidence-explanation">While bats are strongly suspected to be the natural reservoir, the virus has not been isolated definitively from them, providing partial but not conclusive support.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/26757869" target="_blank">PMID:26757869</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Fruits bats are its natural reservoir, the transmission to humans is across wild animals (especially primates) and the propagation in human populations is through bodily fluid contact"</div>
                
                
                <div class="evidence-explanation">This literature indicates that fruit bats are considered the natural reservoir for Ebola, supporting the statement.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">🔬</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">2</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Ebola Virus Antigen
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Positive)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/26874083" target="_blank">PMID:26874083</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The diagnosis of Ebola virus disease relies on the detection of viral RNA in blood by real-time reverse-transcription PCR."</div>
                
                
                <div class="evidence-explanation">This reference clearly states that real-time RT-PCR is used for detecting Ebola viral RNA in blood, supporting the part of the statement related to RT-PCR.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/28887479" target="_blank">PMID:28887479</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"We have developed a reduced graphene oxide-based field-effect transistor method for real-time detection of the Ebola virus antigen."</div>
                
                
                <div class="evidence-explanation">This reference provides additional support for antigen detection methods, which indirectly supports the overall assertion.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Ebola Virus RNA
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Positive)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/26874083" target="_blank">PMID:26874083</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The diagnosis of Ebola virus disease relies on the detection of viral RNA in blood by real-time reverse-transcription PCR."</div>
                
                
                <div class="evidence-explanation">This reference directly supports the statement that RT-PCR assays are used to detect the presence of Ebola Virus RNA.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/26465681" target="_blank">PMID:26465681</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"BACKGROUND: Ebola virus has been detected in the semen of men after their recovery from Ebola virus disease (EVD)... Semen specimens obtained at baseline were tested by means of a quantitative reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay..."</div>
                
                
                <div class="evidence-explanation">This reference also supports the usage of RT-PCR assays for detecting Ebola Virus RNA in biological samples.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Ebola Virus Disease (EVD)
categories:
- Viral Hemorrhagic Fever
- Zoonotic Infectious Disease
has_subtypes:
- name: Zaire Ebolavirus
  description: The most common and deadliest strain, responsible for the majority
    of Ebola outbreaks.
  geography:
  - Democratic Republic of Congo
  - Gabon
  evidence:
  - reference: PMID:8800808
    supports: SUPPORT
    snippet: The reemergence of Ebola, subtype Zaire, in Kikwit 1995 caused a worldwide
      sensation, since it struck after a sensibilization on the danger of Ebola virus
      disease.
    explanation: The Zaire ebolavirus is indeed one of the subtypes of Ebola virus.
      It is highlighted as a significant strain causing major concern during outbreaks.
  - reference: PMID:23327370
    supports: SUPPORT
    snippet: The re-emergence of EHF outbreaks in Gabon and Republic of the Congo
      were concomitant with an increase in mortality amongst gorillas and chimpanzees
      infected with ZEBOV.
    explanation: This reference highlights the re-emergence of outbreaks in the specified
      locations and underscores the high mortality rates associated with the Zaire
      strain of the Ebola virus.
  - reference: PMID:24795448
    supports: SUPPORT
    snippet: The causative agent has now been identified as an outlier strain of Zaire
      Ebola virus.
    explanation: This reference confirms that the virus responsible for the outbreak
      is a strain of Zaire Ebola virus, supporting the statement&#39;s claim about the
      locations and the strain.
- name: Sudan Ebolavirus
  description: Second most prevalent strain, associated with large outbreaks in Africa.
  geography:
  - Sudan
  - Uganda
  evidence:
  - reference: PMID:37750724
    supports: SUPPORT
    snippet: Here, the 2022 Sudan virus disease (SVD) outbreak in Mubende District,
      Uganda, is summarized.
    explanation: This reference indicates that Sudan virus disease (SVD), one of the
      strains of Ebola Virus Disease (EVD), is associated with outbreaks in Uganda.
  - reference: PMID:28643203
    supports: SUPPORT
    snippet: &#39;Ebola virus disease (EVD) in humans is associated with four ebolaviruses:
      Ebola virus (EBOV), Sudan virus (SUDV), Bundibugyo virus (BDBV), and Taï Forest
      virus&#39;
    explanation: This reference confirms that the Sudan virus (SUDV) is a known subtype
      of Ebola virus disease.
  - reference: PMID:31806422
    supports: SUPPORT
    snippet: The genus Ebolavirus from the family Filoviridae is composed of five
      species including Sudan ebolavirus.
    explanation: This reference lists Sudan ebolavirus as one of the species in the
      genus Ebolavirus, supporting the statement that it is a subtype.
  - reference: PMID:37355146
    supports: SUPPORT
    snippet: In 1976, the disease emerged in two simultaneous outbreaks in Sudan and
      the Democratic Republic of Congo.
    explanation: This reference supports the history of outbreaks in Sudan, correlating
      with the Sudan ebolavirus strain.
  - reference: PMID:34420499
    supports: SUPPORT
    snippet: The second largest Ebola virus disease (EVD) epidemic occurred in the
      Democratic Republic of the Congo (DRC) from 2018-20.
    explanation: Although this reference does not specifically mention Sudan ebolavirus,
      it alludes to significant EVD outbreaks in Africa, indirectly supporting the
      assertion about large outbreaks.
- name: Bundibugyo Ebolavirus
  description: Identified in Uganda, this strain has caused smaller outbreaks.
  geography:
  - Uganda
  evidence:
  - reference: PMID:21122234
    supports: SUPPORT
    snippet: The first known Ebola hemorrhagic fever (EHF) outbreak caused by Bundibugyo
      Ebola virus occurred in Bundibugyo District, Uganda, in 2007. Fifty-six cases
      of EHF were laboratory confirmed.
    explanation: This reference supports the statement by confirming the occurrence
      of a Bundibugyo Ebola virus outbreak in Uganda.
  - reference: PMID:34467242
    supports: SUPPORT
    snippet: Bundibugyo virus (BDBV) is one of four ebolaviruses known to cause disease
      in humans. Bundibugyo virus disease (BVD) outbreaks occurred in 2007-2008 in
      Bundibugyo District, Uganda, and in 2012 in Isiro, Province Orientale, Democratic
      Republic of the Congo.
    explanation: This reference also supports the statement by citing outbreaks of
      Bundibugyo Ebola virus in Uganda.
- name: Taï Forest Ebolavirus
  description: Known for a single outbreak in the Ivory Coast.
  geography:
  - Ivory Coast
  evidence:
  - reference: PMID:28643203
    supports: SUPPORT
    snippet: &#39;Ebola virus disease (EVD) in humans is associated with four ebolaviruses:
      Ebola virus (EBOV), Sudan virus (SUDV), Bundibugyo virus (BDBV), and Taï Forest
      virus&#39;
    explanation: The literature states that Tai Forest virus is indeed one of the
      ebolaviruses and mentions its association with human Ebola virus disease (EVD),
      supporting the claim of a known outbreak in Ivory Coast.
  - reference: PMID:31806422
    supports: SUPPORT
    snippet: The genus Ebolavirus from the family Filoviridae is composed of five
      species including Sudan ebolavirus, Reston ebolavirus, Bundibugyo ebolavirus,
      Taï Forest ebolavirus, and Ebola virus (previously known as Zaire ebolavirus)
    explanation: The reference lists Tai Forest ebolavirus as one of the species within
      the genus Ebolavirus, supporting the claim that it is a subtype of Ebola virus
      disease.
  - reference: PMID:37750724
    supports: NO_EVIDENCE
    snippet: Here, the 2022 Sudan virus disease (SVD) outbreak in Mubende District,
      Uganda, is summarized, and the genetic relatedness of the new variant is evaluated.
    explanation: This reference discusses the Sudan virus disease outbreak in Uganda
      in 2022 and does not mention the Tai Forest ebolavirus or outbreaks in Ivory
      Coast.
- name: Reston Ebolavirus
  description: Only strain identified outside Africa; found in the Philippines and
    has not caused disease in humans.
  geography:
  - Philippines
  evidence:
  - reference: PMID:21987747
    supports: PARTIAL
    snippet: Reston ebolavirus infection event in domestic pigs has triggered continuing
      epidemiologic investigations among Philippine health and veterinary agencies...
      The first one in 1989 was the first-ever Ebola virus that emerged outside of
      Africa and was also the first known natural infection of Ebola virus in nonhuman
      primates.
    explanation: The reference supports that Reston ebolavirus was identified outside
      of Africa in the Philippines and that it had not caused disease in humans, but
      it does not affirmatively state that it is the only strain identified outside
      of Africa.
  - reference: PMID:28643203
    supports: SUPPORT
    snippet: To date, no documented cases of human disease have been associated with
      Reston virus.
    explanation: This reference supports the claim that Reston ebolavirus has not
      caused disease in humans.
prevalence:
- population: Central and West Africa
  percentage: Outbreak-dependent
  evidence:
  - reference: PMID:31002071
    supports: SUPPORT
    snippet: Our results suggest a serologic prevalence of 2%-3.5% in the Republic
      of the Congo and the Democratic Republic of the Congo, which have reported outbreaks
      of infection with EBOV. In addition we detected a seroprevalence of 1.3% in
      southern Cameroon, which indicated a low risk for exposure in this region.
    explanation: The study shows variation in serologic prevalence of EBOV in different
      regions of Central Africa, which supports the statement that EVD prevalence
      is outbreak-dependent and varies by region in Central Africa.
  - reference: PMID:34077889
    supports: SUPPORT
    snippet: &#39;The most EVD-affected countries were the Democratic Republic of Congo
      with five outbreaks and a pooled CFR of 65% (95% CI: 59-71%), followed by Uganda
      with three outbreaks and CFR of 83% (95% CI: 60-99%).&#39;
    explanation: This meta-analysis shows varying case fatality rates and the prevalence
      of EVD outbreaks in Central Africa, supporting the statement that the prevalence
      is outbreak-dependent.
progression:
- phase: Onset
  incubation_days: 2-21
  evidence:
  - reference: PMID:25763588
    supports: SUPPORT
    snippet: The incubation period of the disease ranges from 2 to 21 days.
    explanation: The literature specifies that the incubation period for Ebola virus
      disease ranges from 2 to 21 days, which aligns with the statement provided.
infectious_agent:
- name: Ebola Virus
  infectious_agent_term:
    preferred_term: Ebola virus
    term:
      id: NCBITaxon:1570291
      label: Ebola virus
  evidence:
  - reference: PMID:32080199
    supports: SUPPORT
    snippet: Ebola virus disease (EVD) is a severe and frequently lethal disease caused
      by Ebola virus (EBOV).
    explanation: The literature clearly states that EVD is caused by the Ebola virus.
  - reference: PMID:28643203
    supports: SUPPORT
    snippet: &#39;Ebola virus disease (EVD) in humans is associated with four ebolaviruses:
      Ebola virus (EBOV), Sudan virus (SUDV), Bundibugyo virus (BDBV), and Taï Forest
      virus&#39;
    explanation: This reference confirms that Ebola virus (EBOV) is indeed an infectious
      agent of EVD.
  - reference: PMID:24040779
    supports: SUPPORT
    snippet: Since Ebola virus was discovered in 1970s, the virus has persisted in
      Africa and sporadic fatal outbreaks in humans and non-human primates have been
      reported.
    explanation: This reference states that Ebola virus is responsible for outbreaks
      in humans, indicating it as the infectious agent for Ebola virus disease.
  - reference: PMID:33734027
    supports: SUPPORT
    snippet: Ebola virus (EBOV), belonging to the species Zaire ebolavirus in the
      genus Ebolavirus, causes a severe febrile illness in humans with case fatality
      rates (CFRs) up to 90%.
    explanation: This literature directly links Ebola virus (EBOV) to the severe illness
      known as Ebola Virus Disease (EVD).
transmission:
- name: Direct Fluid Transmission
  description: Virus is transmitted through direct contact with the blood, secretions,
    organs, or other bodily fluids of infected individuals or animals.
  evidence: []
- name: Contaminated Surfaces
  description: The virus can survive on surfaces, infecting individuals through contact
    with these contaminated surfaces.
  evidence:
  - reference: PMID:25698835
    supports: PARTIAL
    snippet: Available evidence demonstrates that direct patient contact and contact
      with infectious body fluids are the primary modes for Ebola virus transmission,
      but this is based on a limited number of studies. Key areas requiring further
      study include... (ii) the role of environmental contamination and fomite transmission...
    explanation: While the reference acknowledges the role of environmental contamination
      and fomite transmission, it indicates that this is an area that requires further
      study and is not yet conclusively established as a primary mode of transmission.
phenotypes:
- category: Systemic
  name: Fever
  frequency: VERY_FREQUENT
  diagnostic: true
  evidence:
  - reference: PMID:32080199
    supports: SUPPORT
    snippet: EVD has a high case-fatality rate; it is characterized by fever, gastrointestinal
      signs and multiple organ dysfunction syndrome.
    explanation: The literature indicates that fever is a very frequent symptom of
      Ebola Virus Disease (EVD).
  - reference: PMID:28457350
    supports: SUPPORT
    snippet: This review highlights the range of aspects of EVD that the authors find
      are relevant to laboratory medicine, including the need for robust prediagnostic
      and laboratory processing algorithms to inform sampling of suspect patients,
      the vast majority of whom, in resource-rich settings, will have another diagnosis.
    explanation: The background is specific to diagnostic issues for laboratory professionals,
      indicating the relevance of fever as a primary symptom for suspect cases during
      prediagnostic processes.
  phenotype_term:
    preferred_term: Fever
    term:
      id: HP:0001945
      label: Fever
- category: Systemic
  name: Hemorrhage
  severity: Severe
  frequency: VERY_FREQUENT
  diagnostic: true
  evidence:
  - reference: PMID:32487785
    supports: SUPPORT
    snippet: It is usually diagnosed based on several clinical symptoms such as the
      sudden onset of illness, high fevers for less than three weeks, and at least
      two hemorrhagic symptoms despite no predisposing factors.
    explanation: The literature confirms that hemorrhagic symptoms are a key diagnostic
      feature of EVD.
  - reference: PMID:28484180
    supports: SUPPORT
    snippet: Ebolaviruses, members of the family Filoviridae, cause severe hemorrhagic
      fever in humans and nonhuman primates, with human case fatality rates of up
      to 90%.
    explanation: The literature confirms severe hemorrhagic fever as a phenotype of
      EVD.
  - reference: PMID:30893774
    supports: SUPPORT
    snippet: Ebola Virus Disease (EVD) is one of the most lethal transmissible infections,
      characterized by a high fatality rate, and caused by a member of the Filoviridae
      family.
    explanation: The literature supports that EVD is a severe systemic disease with
      high fatality, implying high frequency and severity of symptoms like hemorrhage.
  - reference: PMID:35657325
    supports: SUPPORT
    snippet: &#39;A group of viruses within the genus Ebolavirus causes this severe hemorrhagic
      disease in humans: Ebola virus (EBOV; species Zaire ebolavirus), Sudan virus
      (SUDV; species Sudan ebolavirus), Bundibugyo virus, and Taï Forest virus&#39;
    explanation: The literature supports that EVD is characterized by severe systemic
      symptoms, including severe hemorrhagic manifestations.
  sequelae:
  - target: Hypovolemic Shock
  - target: Multiorgan Failure
  - target: Vascular Dysfunction and Death
    description: Ebola virus causes aggressive inflammatory response and impaired
      coagulation systems leading to hemorrhage and often death.
    evidence:
    - reference: PMID:35446128
      supports: SUPPORT
      snippet: Ebola virus (EBV) disease (EVD) is a highly virulent systemic disease
        characterized by an aggressive systemic inflammatory response and impaired
        vascular and coagulation systems, often leading to uncontrolled hemorrhaging
        and death.
      explanation: This paper establishes that Ebola virus causes systemic inflammatory
        response and coagulation impairment leading to hemorrhage and death.
  phenotype_term:
    preferred_term: Hemorrhage
    term:
      id: HP:0001892
      label: Abnormal bleeding
- category: Gastrointestinal
  name: Vomiting
  severity: Severe
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:25972150
    supports: PARTIAL
    snippet: Common gastrointestinal manifestations include...nausea and vomiting-60%...The
      diarrhea and nausea and vomiting frequently produce profound, life-threatening
      hypovolemia.
    explanation: While vomiting is a common manifestation and can lead to severe consequences
      like life-threatening hypovolemia, the literature does not specifically categorize
      vomiting itself as &#34;severe.&#34; The severity is associated with the complications
      resulting from vomiting and other symptoms.
  - reference: PMID:32080199
    supports: PARTIAL
    snippet: EVD outbreaks typically start from a single case of probable zoonotic
      transmission, followed by human-to-human transmission via direct contact or
      contact with infected bodily fluids or contaminated fomites. EVD has a high
      case-fatality rate; it is characterized by fever, gastrointestinal signs and
      multiple organ dysfunction syndrome.
    explanation: This reference indicates the inclusion of gastrointestinal signs
      in EVD, which can imply vomiting, but does not specifically mention the frequency
      or severity of vomiting.
  - reference: PMID:27717513
    supports: PARTIAL
    snippet: The clinical spectrum of Ebola virus disease (EVD) ranges from very serious
      forms with organ failure and death within days to paucisymptomatic forms and
      perhaps even asymptomatic.
    explanation: This suggests variability in EVD presentation, acknowledging severe
      forms, but it does not specify the severity or frequency of vomiting in particular.
  phenotype_term:
    preferred_term: Vomiting
    term:
      id: HP:0002013
      label: Vomiting
- category: Gastrointestinal
  name: Diarrhea
  severity: Severe
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:32080199
    supports: SUPPORT
    snippet: EVD has a high case-fatality rate; it is characterized by fever, gastrointestinal
      signs and multiple organ dysfunction syndrome.
    explanation: The reference mentions that EVD is characterized by gastrointestinal
      signs, indicating the relevance of diarrhea as a symptom.
  - reference: PMID:25972150
    supports: SUPPORT
    snippet: Common gastrointestinal manifestations include diarrhea-70 %.
    explanation: This directly supports the statement by noting that diarrhea is a
      common (70% frequency) gastrointestinal manifestation.
  - reference: PMID:34986351
    supports: SUPPORT
    snippet: During the 2013-2016 West African (WA) Ebola virus (EBOV) outbreak, severe
      gastrointestinal symptoms were common in patients and associated with poor outcome.
    explanation: The reference highlights that severe gastrointestinal symptoms, including
      diarrhea, were common and associated with poor outcomes.
  sequelae:
  - target: Dehydration
  - target: Electrolyte Imbalances
  phenotype_term:
    preferred_term: Diarrhea
    term:
      id: HP:0002014
      label: Diarrhea
- category: Dermatologic
  name: Maculopapular Rash
  frequency: FREQUENT
  evidence:
  - reference: PMID:25780982
    supports: SUPPORT
    snippet: The main cutaneous finding of Ebola is a nonspecific maculopapular rash
      that appears between day four and six of disease.
    explanation: The statement is supported as the primary dermatologic phenotype
      associated with Ebola Virus Disease (EVD) is a nonspecific maculopapular rash,
      and it is noted as a main cutaneous finding.
- category: Systemic
  frequency: VERY_FREQUENT
  name: Fatigue
  evidence:
  - reference: PMID:38840082
    supports: PARTIAL
    snippet: &#39;The pooled prevalence was... fatigue 25% (95% CI: 19%-31%)&#39;
    explanation: Fatigue is reported as a symptom in 25% of EVD survivors, which indicates
      it is relatively common but not &#39;very frequent&#39; as the statement suggests.
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
- category: Musculoskeletal
  frequency: FREQUENT
  name: Myalgia
  evidence:
  - reference: PMID:38840082
    supports: SUPPORT
    snippet: &#39;The pooled prevalence was: arthralgia 50% (95% CI: 41%-59%); headache
      44% (95% CI: 36%-52%); myalgia 32% (95% CI: 26%-38%)&#39;
    explanation: The meta-analysis shows that myalgia has a pooled prevalence of 32%
      among Ebola Virus Disease (EVD) survivors, indicating it is a frequent musculoskeletal
      symptom.
  phenotype_term:
    preferred_term: Myalgia
    term:
      id: HP:0003326
      label: Myalgia
- category: Neurologic
  frequency: OCCASIONAL
  name: Headache
  evidence:
  - reference: PMID:31874716
    supports: SUPPORT
    snippet: The main clinical signs were asthenia (78.8%), fever (75.3%), anorexia
      (53.4%), headache (45.9%)...
    explanation: This study lists headache as one of the main clinical signs in children
      with EVD, supporting the statement that headache is an occasional neurologic
      symptom of EVD.
  - reference: PMID:33493959
    supports: SUPPORT
    snippet: In patients with EVD, neurologic manifestations range from mild symptoms
      such as confusion to severe neurologic diseases such as meningitis and encephalitis.
      Altered mental status, from mild confusion to delirium with hallucinations,
      may also occur.
    explanation: While this reference does not explicitly mention headache, it discusses
      a range of neurologic symptoms in EVD patients, suggesting that neurologic symptoms,
      including headache, can occur occasionally.
  - reference: PMID:26983037
    supports: SUPPORT
    snippet: Survivors reported musculoskeletal pain (70%), headache (48%), and ocular
      problems (14%).
    explanation: This study reports that 48% of EVD survivors experienced headaches,
      supporting the statement that headache is an occasional neurologic symptom of
      EVD.
  phenotype_term:
    preferred_term: Headache
    term:
      id: HP:0002315
      label: Headache
- category: Gastrointestinal
  frequency: FREQUENT
  name: Abdominal Pain
  evidence:
  - reference: PMID:25972150
    supports: SUPPORT
    snippet: Common gastrointestinal manifestations include diarrhea-70 %, nausea
      and vomiting-60 %, and abdominal pain-45 %.
    explanation: The literature indicates that abdominal pain occurs in 45% of EVD
      cases, supporting the claim that it is a frequent gastrointestinal manifestation.
  - reference: PMID:31874716
    supports: SUPPORT
    snippet: The main clinical signs were asthenia (78.8%), fever (75.3%), anorexia
      (53.4%), headache (45.9%), vomiting (41.8%), abdominal pain (29.5%), and diarrhea
      (28.8%).
    explanation: The study shows that abdominal pain was observed in 29.5% of children
      with EVD, supporting the statement that it is a frequent gastrointestinal symptom.
  phenotype_term:
    preferred_term: Abdominal pain
    term:
      id: HP:0002027
      label: Abdominal pain
- category: Hematologic
  frequency: FREQUENT
  name: Thrombocytopenia
  sequelae:
  - target: Increased Risk of Bleeding
  evidence:
  - reference: PMID:32487785
    supports: PARTIAL
    snippet: Transmission of EBoV has been reported in various ways, including human
      to human transmission through close contact with blood and bodily fluids...
      It is usually diagnosed based on several clinical symptoms such as the sudden
      onset of illness, high fevers for less than three weeks, and at least two hemorrhagic
      symptoms despite no predisposing factors.
    explanation: The literature mentions hemorrhagic symptoms but does not specifically
      mention thrombocytopenia or its frequency.
  - reference: PMID:25679971
    supports: PARTIAL
    snippet: Understanding bleeding in Ebola virus disease.
    explanation: The reference discusses bleeding in Ebola virus disease but does
      not specifically mention thrombocytopenia or its frequency.
  - reference: PMID:35446128
    supports: PARTIAL
    snippet: Ebola virus (EBV) disease (EVD) is a highly virulent systemic disease
      characterized by an aggressive systemic inflammatory response and impaired vascular
      and coagulation systems, often leading to uncontrolled hemorrhaging and death.
    explanation: The literature discusses impaired vascular and coagulation systems,
      which can be related to thrombocytopenia, but does not specifically mention
      its frequency.
  phenotype_term:
    preferred_term: Thrombocytopenia
    term:
      id: HP:0001873
      label: Thrombocytopenia
- category: Hepatic
  frequency: FREQUENT
  name: Hepatitis
  sequelae:
  - target: Elevated Liver Enzymes
  - target: Impaired Liver Function
  evidence:
  - reference: PMID:2822180
    supports: PARTIAL
    snippet: Even though HAV, HBV and HNANB viruses are responsible for most of the
      viral hepatitis cases, many other viruses have been reported to cause hepatic
      injury. These viruses may involve the liver, either as part of a systemic illness
      (e.g. EBV, CMV, HSV) or as the primary target organ (e.g. yellow fever virus,
      Lassa fever virus, Ebola virus). Clinically overt hepatocellular dysfunction
      is rare in such viral infections.
    explanation: The reference indicates that Ebola virus can cause hepatic injury,
      but clinically overt hepatocellular dysfunction is rare. This partially supports
      the statement as it acknowledges hepatic involvement but suggests that severe
      liver dysfunction is not frequent.
  - reference: PMID:25972150
    supports: PARTIAL
    snippet: The mean serum AST and ALT levels are each about 200/UL, with an unusual
      pattern for viral hepatitis of AST &gt; ALT.
    explanation: The reference indicates elevated liver enzymes (AST and ALT) in Ebola
      virus infection, which supports the part of the statement regarding elevated
      liver enzymes. However, it does not confirm frequent impaired liver function
      or hepatitis as a common sequela.
  - reference: PMID:37170900
    supports: PARTIAL
    snippet: Results illustrate that EBOV causes macrophage phenotype alterations
      as well as neutrophil influx and prominent activation of interferon host responses
      in the liver.
    explanation: The reference provides evidence of liver involvement and immune response
      alterations in Ebola virus infection, which can be associated with hepatic dysfunction.
      However, it does not explicitly state that hepatitis or impaired liver function
      is frequent.
  - reference: PMID:29020340
    supports: NO_EVIDENCE
    snippet: The role of the virus in liver damage remains unclear, but our evidence
      suggests that acute severe liver injury is not a typical feature of Ebola virus
      disease.
    explanation: The reference suggests that acute severe liver injury is not typical
      in Ebola virus disease, which refutes the statement that impaired liver function
      is frequent.
  phenotype_term:
    preferred_term: Hepatitis
    term:
      id: HP:0012115
      label: Hepatitis
- category: Systemic
  name: Hypovolemic Shock
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Hypovolemic Shock
    term:
      id: HP:0031273
      label: Shock
- category: Systemic
  name: Dehydration
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Dehydration
    term:
      id: HP:0001944
      label: Dehydration
- category: Metabolic
  name: Electrolyte Imbalances
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Electrolyte Imbalances
    term:
      id: HP:0003111
      label: Abnormal blood ion concentration
- name: Multiorgan Failure
  frequency: FREQUENT
  notes: HPO does not have a specific term for multiple organ dysfunction syndrome
  phenotype_term:
    preferred_term: Multiorgan Failure
- name: Elevated Liver Enzymes
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Elevated Liver Enzymes
    term:
      id: HP:0002910
      label: Elevated circulating hepatic transaminase concentration
- name: Impaired Liver Function
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Impaired Liver Function
    term:
      id: HP:0001410
      label: Decreased liver function
- name: Increased Risk of Bleeding
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Increased Risk of Bleeding
    term:
      id: HP:0001892
      label: Abnormal bleeding
biochemical:
- name: Ebola Virus Antigen
  presence: Positive
  assays:
  - preferred_term: Antigen-Capture Enzyme-Linked Immunosorbent Assay (ELISA)
  - preferred_term: Reverse Transcription Polymerase Chain Reaction (RT-PCR)
  evidence:
  - reference: PMID:26874083
    supports: SUPPORT
    snippet: The diagnosis of Ebola virus disease relies on the detection of viral
      RNA in blood by real-time reverse-transcription PCR.
    explanation: This reference clearly states that real-time RT-PCR is used for detecting
      Ebola viral RNA in blood, supporting the part of the statement related to RT-PCR.
  - reference: PMID:28887479
    supports: SUPPORT
    snippet: We have developed a reduced graphene oxide-based field-effect transistor
      method for real-time detection of the Ebola virus antigen.
    explanation: This reference provides additional support for antigen detection
      methods, which indirectly supports the overall assertion.
- name: Ebola Virus RNA
  presence: Positive
  assays:
  - preferred_term: Reverse Transcription Polymerase Chain Reaction (RT-PCR)
  evidence:
  - reference: PMID:26874083
    supports: SUPPORT
    snippet: The diagnosis of Ebola virus disease relies on the detection of viral
      RNA in blood by real-time reverse-transcription PCR.
    explanation: This reference directly supports the statement that RT-PCR assays
      are used to detect the presence of Ebola Virus RNA.
  - reference: PMID:26465681
    supports: SUPPORT
    snippet: &#39;BACKGROUND: Ebola virus has been detected in the semen of men after
      their recovery from Ebola virus disease (EVD)... Semen specimens obtained at
      baseline were tested by means of a quantitative reverse-transcriptase-polymerase-chain-reaction
      (RT-PCR) assay...&#39;
    explanation: This reference also supports the usage of RT-PCR assays for detecting
      Ebola Virus RNA in biological samples.
environmental:
- name: Animal Reservoirs
  notes: Fruit bats are considered the natural hosts; transmission also occurs through
    handling of infected wild animals.
  evidence:
  - reference: PMID:17848072
    supports: SUPPORT
    snippet: &#39;Among the various animals captured and analyzed, three species of fruit
      bats (suborder Megachiroptera) were found asymptomatically and naturally infected
      with Ebola virus: Hypsignathus monstrosus (hammer-headed fruit beats), Epomops
      franqueti (singing fruit bats), and Myonycteris torquata (little collared fruit
      bats)&#39;
    explanation: This study confirms that certain species of fruit bats serve as Ebola
      virus reservoirs, supporting the notion that fruit bats are natural hosts of
      the virus.
  - reference: PMID:28573636
    supports: PARTIAL
    snippet: Although an ebolavirus natural reservoir has yet to be identified, the
      majority of disease ecologists believe the reservoir to belong to the order
      Chiroptera (bats).
    explanation: While bats are strongly suspected to be the natural reservoir, the
      virus has not been isolated definitively from them, providing partial but not
      conclusive support.
  - reference: PMID:26757869
    supports: SUPPORT
    snippet: Fruits bats are its natural reservoir, the transmission to humans is
      across wild animals (especially primates) and the propagation in human populations
      is through bodily fluid contact
    explanation: This literature indicates that fruit bats are considered the natural
      reservoir for Ebola, supporting the statement.
  - reference: PMID:26147380
    supports: SUPPORT
    snippet: Ebola virus disease (EVD) is a zoonotic disease that causes severe haemorrhagic
      fever, with high fatality rates of up to 90% in humans.
    explanation: This reference identifies EVD as a zoonotic disease, implying the
      involvement of animal reservoirs.
  exposure_term:
    preferred_term: Animal reservoir exposure
    term:
      id: ECTO:3000001
      label: exposure to virus
pathophysiology:
- name: Viral Entry via Endocytosis
  description: Ebola virus enters host cells through receptor-mediated macropinocytosis.
    The virus attaches to phosphatidylserine receptors like TIM-1 (HAVCR1) and is
    internalized into endosomes. Cathepsins B and L cleave the viral glycoprotein
    (GP), followed by binding to the essential receptor NPC1 in late endosomes/lysosomes,
    triggering membrane fusion and release of viral genome into the cytoplasm.
  cell_types:
  - preferred_term: monocyte
    term:
      id: CL:0000576
      label: monocyte
  - preferred_term: macrophage
    term:
      id: CL:0000235
      label: macrophage
  - preferred_term: dendritic cell
    term:
      id: CL:0000451
      label: dendritic cell
  biological_processes:
  - preferred_term: symbiont entry into host cell
    term:
      id: GO:0046718
      label: symbiont entry into host cell
  notes: NPC1, HAVCR1 (TIM-1), SLC39A9, PIK3C3, and cathepsins are critical host
    factors. The process depends on macropinocytosis and late endosomal cholesterol
    transport.
- name: Immune Evasion and Viral Replication
  description: Ebola viral proteins VP35 and VP24 antagonize the host interferon
    response. VP35 binds dsRNA and blocks RIG-I signaling, while VP24 prevents STAT1
    nuclear import, thereby suppressing type I interferon signaling. This allows
    rapid viral replication and high viremia in infected monocytes, macrophages,
    and dendritic cells.
  cell_types:
  - preferred_term: monocyte
    term:
      id: CL:0000576
      label: monocyte
  - preferred_term: macrophage
    term:
      id: CL:0000235
      label: macrophage
  - preferred_term: dendritic cell
    term:
      id: CL:0000451
      label: dendritic cell
  notes: VP35 and VP24 are multifunctional proteins that integrate polymerase cofactor
    roles with immune evasion. Secreted GP (sGP) may act as an antibody decoy.
- name: Endothelial Dysfunction and Vascular Leak
  description: Ebola virus glycoprotein (GP) and secreted GP (sGP) contribute to
    endothelial cell activation and barrier disruption. This leads to increased vascular
    permeability, fluid extravasation, and hypovolemic shock. Endothelial dysfunction
    is a central feature of Ebola hemorrhagic fever.
  cell_types:
  - preferred_term: endothelial cell
    term:
      id: CL:0000115
      label: endothelial cell
  locations:
  - preferred_term: blood vessel
    term:
      id: UBERON:0001981
      label: blood vessel
  notes: GP-mediated endothelial perturbations and inflammatory signaling drive shock
    in viral hemorrhagic fevers. Glycocalyx disruption and loss of adherens junction
    integrity contribute to vascular leak.
- name: Coagulopathy and Disseminated Intravascular Coagulation
  description: Ebola infection triggers systemic inflammatory response with cytokine
    release, endothelial activation, and tissue factor pathway activation. This leads
    to thromboinflammation, platelet activation, consumptive coagulopathy, and disseminated
    intravascular coagulation (DIC), resulting in hemorrhagic manifestations.
  biological_processes:
  - preferred_term: blood coagulation
    term:
      id: GO:0007596
      label: blood coagulation
  locations:
  - preferred_term: blood vessel
    term:
      id: UBERON:0001981
      label: blood vessel
  notes: Impaired coagulation systems with uncontrolled hemorrhaging characterize
    severe EVD. Thrombocytopenia and elevated liver enzymes are common laboratory
    findings.
- name: Multiorgan Involvement
  description: Ebola virus infects multiple organs including liver, spleen, lymph
    nodes, and kidneys. Hepatic dysfunction with elevated liver enzymes (AST &gt; ALT
    pattern) and splenic involvement contribute to multiorgan failure in severe cases.
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  - preferred_term: spleen
    term:
      id: UBERON:0002106
      label: spleen
  notes: Liver involvement manifests with elevated AST and ALT (unusual AST &gt; ALT
    pattern). Macrophage activation and cytokine storm contribute to organ damage.
treatments:
- name: Supportive Care
  description: Includes rehydration, symptomatic treatment to manage fever, bleeding,
    and pain.
  evidence:
  - reference: PMID:37355146
    supports: SUPPORT
    snippet: Early detection and supportive care can enhance the likelihood of survival.
      This includes intravenous fluids, electrolyte replacement, and treatment of
      secondary infections.
    explanation: The provided literature supports that supportive care, including
      rehydration and symptomatic treatment, is a key component in the treatment of
      Ebola Virus Disease (EVD).
  - reference: PMID:28646340
    supports: SUPPORT
    snippet: Clinical management of EVD combines supportive and symptomatic care while
      also addressing the patient&#39;s emotional and mental health needs.
    explanation: This literature indicates the combination of supportive and symptomatic
      care is part of the clinical management of EVD.
  - reference: PMID:29054555
    supports: SUPPORT
    snippet: Key recommendations include administration of oral and, as necessary,
      intravenous hydration; systematic monitoring of vital signs and volume status;
      availability of key biochemical testing; adequate staffing ratios; and availability
      of analgesics, including opioids, for pain relief.
    explanation: The evidence-based guidelines for supportive care of patients with
      EVD include recommendations that align with rehydration and symptomatic treatments
      for managing fever, bleeding, and pain.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
- name: Experimental Therapies
  description: Includes antiviral drugs, immune therapies, and blood products from
    survivors containing antibodies.
  evidence:
  - reference: PMID:27337455
    supports: SUPPORT
    snippet: The armamentarium against EVD eventually included biologics such as monoclonal
      antibodies, convalescent plasma, and vaccines as well as small molecule therapeutics
      such as small interfering RNAs and nucleoside analogs.
    explanation: The reference mentions the use of various experimental therapies
      including immune therapies (monoclonal antibodies), blood products (convalescent
      plasma), and small molecule therapeutics (antiviral drugs).
  - reference: PMID:11766882
    supports: SUPPORT
    snippet: This review describes Ebola viruses, with a particular focus on the status
      of research efforts to develop vaccines and therapeutics and to identify the
      immune mechanisms of protection.
    explanation: The reference highlights the ongoing research for developing therapeutics,
      including immune mechanisms for protection, which aligns with the statement.
  - reference: PMID:25457751
    supports: SUPPORT
    snippet: Recently, the use of convalescent blood products was proposed by the
      WHO as one early option for treating patients with Ebola virus disease.
    explanation: The reference confirms the use of convalescent blood products as
      a treatment strategy for EVD, supporting the statement.
  - reference: PMID:32487785
    supports: SUPPORT
    snippet: &#39;Management of patients involves supportive care such as maintaining
      fluid along with electrolyte balance, blood pressure and oxygen saturation.
      This also includes treating complications arising from secondary infections.
      The main options include: prophylactic strategies, anti-viral therapy for EVD,
      immunotherapies, vaccines, and ZMapp.&#39;
    explanation: The reference lists anti-viral therapy and immunotherapies as main
      treatment options, confirming the statement&#39;s reference to experimental therapies.
  - reference: PMID:30943399
    supports: SUPPORT
    snippet: We describe therapeutic monoclonal antibodies isolated from human volunteers
      vaccinated with recombinant adenovirus expressing Ebola virus glycoprotein (EBOV
      GP).
    explanation: The reference discusses therapeutic monoclonal antibodies, which
      are a form of immune therapy, in line with the statement.
  treatment_term:
    preferred_term: antiviral agent therapy
    term:
      id: MAXO:0000168
      label: antiviral agent therapy
- name: Vaccination
  description: The rVSV-ZEBOV vaccine has been shown to be effective in preventing
    Ebola infection.
  evidence:
  - reference: PMID:28017403
    supports: SUPPORT
    snippet: The results add weight to the interim assessment that rVSV-ZEBOV offers
      substantial protection against Ebola virus disease, with no cases among vaccinated
      individuals from day 10 after vaccination in both randomised and non-randomised
      clusters.
    explanation: The study shows that rVSV-ZEBOV vaccine offers substantial protection
      against Ebola virus disease, supporting the statement that it is effective in
      preventing Ebola infection.
  - reference: PMID:32243796
    supports: SUPPORT
    snippet: Ervebo is the first licensed vaccine for prevention of Ebola virus disease.
    explanation: The article states that Ervebo (rVSV-ZEBOV) is licensed for the prevention
      of Ebola virus disease, supporting the statement that the vaccine is effective
      in preventing Ebola infection.
  - reference: PMID:33873076
    supports: SUPPORT
    snippet: &#39;Currently, two vaccines: Ervebo (rVSV-ZEBOV) and a two-dose combination
      of Zabdeno (Ad26.ZEBOV) and Mvabea (MVA-BN-Filo) have been licensed and in use.&#39;
    explanation: The abstract mentions that Ervebo (rVSV-ZEBOV) has been licensed
      and is being used to prevent Ebola Virus Disease, supporting the statement that
      it is effective in preventing infection.
  - reference: PMID:34749265
    supports: SUPPORT
    snippet: In 2019, the FDA-approved the first anti-EBOV vaccine, rVSV-EBOV-GP (Ervebo®
      by Merck)
    explanation: The article confirms that the rVSV-EBOV-GP (Ervebo) vaccine is FDA-approved
      and provides prophylactic protection against Ebola, supporting the statement
      that it is effective in preventing Ebola infection.
  treatment_term:
    preferred_term: vaccination
    term:
      id: MAXO:0001017
      label: vaccination
genetic:
- name: NPC1
  association: Host factor
  notes: Niemann-Pick C1 protein is a late endosomal/lysosomal cholesterol transporter
    that serves as the essential receptor for Ebola virus GP-mediated membrane fusion
    and cytosolic entry. Genetic depletion blocks EBOV entry.
- name: HAVCR1
  association: Host factor
  notes: Hepatitis A virus cellular receptor 1 (TIM-1) is a phosphatidylserine receptor
    that serves as an attachment factor for Ebola virus, facilitating viral entry
    into host cells.
- name: SLC39A9
  association: Host factor
  notes: Zinc transporter protein identified by CRISPR screen as a crucial entry
    factor for Ebola virus. Impacts glycosylation processes required for viral internalization.
- name: PIK3C3
  association: Host factor
  notes: Class III phosphatidylinositol 3-kinase (VPS34) identified by CRISPR screen
    as essential for EBOV entry. Its kinase activity is indispensable for the internalization
    of Ebola virions through macropinocytosis.
- name: CTSB
  association: Host factor
  notes: Cathepsin B is an endosomal protease that primes Ebola virus glycoprotein
    (GP) for receptor binding and membrane fusion in late endosomes.
- name: CTSL
  association: Host factor
  notes: Cathepsin L is an endosomal protease that primes Ebola virus glycoprotein
    (GP) for receptor binding and membrane fusion in late endosomes.
review_notes: Ebola is a severe viral hemorrhagic fever. Key features are the sudden
  onset of fever, muscle pain, headache and sore throat, followed by vomiting, diarrhea,
  rash, impaired kidney and liver function, and in some cases, both internal and external
  bleeding. Mortality is high. Transmission occurs through direct contact with bodily
  fluids of infected people or animals.
disease_term:
  preferred_term: Ebola hemorrhagic fever
  term:
    id: MONDO:0005737
    label: Ebola hemorrhagic fever
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Ebola_Virus_Disease_EVD.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
</body>
</html>